These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 23420398)
1. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. Dinglin XX; Huang Y; Liu H; Zeng YD; Hou X; Chen LK J Neurooncol; 2013 May; 112(3):461-6. PubMed ID: 23420398 [TBL] [Abstract][Full Text] [Related]
2. Phase II Study of High-Dose Pemetrexed Plus Cisplatin as First-Line Chemotherapy In the Treatment of Patients with Brain Metastases from Lung Adenocarcinoma. He Q; Wang Y; Zou P; Wang Y; Xiu C; Zhang H; Chi N; Zou H; Xu J; Zhou S; Tao R World Neurosurg; 2017 Mar; 99():758-762. PubMed ID: 27060518 [TBL] [Abstract][Full Text] [Related]
3. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Barlesi F; Gervais R; Lena H; Hureaux J; Berard H; Paillotin D; Bota S; Monnet I; Chajara A; Robinet G Ann Oncol; 2011 Nov; 22(11):2466-2470. PubMed ID: 21321089 [TBL] [Abstract][Full Text] [Related]
4. Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin He Q; Bi X; Ren C; Wang Y; Zou P; Zhang H; Chi N; Xiu C; Wang Y; Tao R Anticancer Res; 2017 Aug; 37(8):4711-4716. PubMed ID: 28739776 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Zhuang H; Yuan Z; Wang J; Zhao L; Pang Q; Wang P Drug Des Devel Ther; 2013; 7():1179-86. PubMed ID: 24133369 [TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. Choy H; Schwartzberg LS; Dakhil SR; Garon EB; Gerber DE; Choksi JK; Govindan R; Peng G; Koustenis A; Treat J; Obasaju C J Thorac Oncol; 2013 Oct; 8(10):1308-16. PubMed ID: 23981966 [TBL] [Abstract][Full Text] [Related]
8. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Chen H; Modiano MR; Neal JW; Brahmer JR; Rigas JR; Jotte RM; Leighl NB; Riess JW; Kuo CJ; Liu L; Gao B; Dicioccio AT; Adjei AA; Wakelee HA Br J Cancer; 2014 Feb; 110(3):602-8. PubMed ID: 24292447 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163 [TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
12. Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study. Kawano Y; Ohyanagi F; Yanagitani N; Kudo K; Horiike A; Tanimoto A; Nishizawa H; Ichikawa A; Sakatani T; Nakatomi K; Hagiwara S; Ninomiya H; Motoi N; Ishikawa Y; Horai T; Nishio M Anticancer Res; 2013 Aug; 33(8):3327-33. PubMed ID: 23898099 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776 [TBL] [Abstract][Full Text] [Related]
14. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Arrieta O; Villarreal-Garza C; Zamora J; Blake-Cerda M; de la Mata MD; Zavala DG; Muñiz-Hernández S; de la Garza J Radiat Oncol; 2011 Nov; 6():166. PubMed ID: 22118497 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216 [TBL] [Abstract][Full Text] [Related]
16. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507 [TBL] [Abstract][Full Text] [Related]
17. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Barlesi F; Scherpereel A; Gorbunova V; Gervais R; Vikström A; Chouaid C; Chella A; Kim JH; Ahn MJ; Reck M; Pazzola A; Kim HT; Aerts JG; Morando C; Loundou A; Groen HJ; Rittmeyer A Ann Oncol; 2014 May; 25(5):1044-52. PubMed ID: 24585722 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404 [TBL] [Abstract][Full Text] [Related]
19. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Bailon O; Chouahnia K; Augier A; Bouillet T; Billot S; Coman I; Ursu R; Belin C; Zelek L; Des Guetz G; Levy C; Carpentier AF; Morere JF Neuro Oncol; 2012 Apr; 14(4):491-5. PubMed ID: 22362813 [TBL] [Abstract][Full Text] [Related]
20. Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review. He G; Xiao X; Zou M; Zhang C; Xia S Medicine (Baltimore); 2016 Aug; 95(32):e4401. PubMed ID: 27512852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]